Literature DB >> 23872864

First-in-class angiotensin receptor neprilysin inhibitor in heart failure.

O Vardeny1, T Tacheny, S D Solomon.   

Abstract

Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23872864     DOI： 10.1038/clpt.2013.146

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Critical Questions about PARADIGM-HF and the Future.

Authors:  Chen-Huan Chen
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

Review 2.  Sacubitril/Valsartan: From Clinical Trials to Real-world Experience.

Authors:  Joanna M Joly; Akshay S Desai
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-23

3.  Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats.

Authors:  Chenchen Zhuang; Wenjuan Wang; Runmin Sun; Miaomiao Qi; Jing Yu
Journal:  J Cardiovasc Pharmacol       Date:  2022-06-01       Impact factor: 3.271

Review 4.  Neprilysin inhibition in chronic kidney disease.

Authors:  Parminder Judge; Richard Haynes; Martin J Landray; Colin Baigent
Journal:  Nephrol Dial Transplant       Date:  2014-08-18       Impact factor: 5.992

Review 5.  Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.

Authors:  Jagdeep S S Singh; Chim C Lang
Journal:  Vasc Health Risk Manag       Date:  2015-06-01

6.  PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

Authors:  Edgardo Kaplinsky
Journal:  J Geriatr Cardiol       Date:  2015-09       Impact factor: 3.327

7.  Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.

Authors:  Takunori Seki; Kenichi Goto; Yasuo Kansui; Toshio Ohtsubo; Kiyoshi Matsumura; Takanari Kitazono
Journal:  J Am Heart Assoc       Date:  2017-10-17       Impact factor: 5.501

8.  Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.

Authors:  Damien Legallois; Clémence Macquaire; Amir Hodzic; Stéphane Allouche; Ismaïl El Khouakhi; Alain Manrique; Paul Milliez; Eric Saloux; Farzin Beygui
Journal:  BMC Cardiovasc Disord       Date:  2020-07-02       Impact factor: 2.298

9.  Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2014-06-03       Impact factor: 15.534

10.  PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?

Authors:  Robert O Bonow; Ahmed M ElGuindy
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.